Absci and AMD Form Strategic Partnership for AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a leader in generative AI for drug development, has announced a significant collaboration with AMD, renowned for its innovations in high-performance computing. This partnership aims to accelerate advancements in AI drug discovery by deploying AMD Instinct™ accelerators and ROCm™ software for complex biological modeling tasks.
Investment to Drive Innovation
As part of this partnership, AMD is making a substantial investment of $20 million in Absci through a private investment in public equity (PIPE). This financial backing underscores the increasing need for innovative AI solutions in the realm of drug development, bridging the gap between technology and therapeutic advancements.
Advancing Drug Discovery Capabilities
Sean McClain, Founder and CEO of Absci, expressed his enthusiasm about the collaboration, indicating that it enhances the efficiency and creativity in drug discovery processes. He highlighted that the integration of AMD's high-performance computing capabilities will empower Absci to further develop next-generation antibody therapeutics, ultimately leading to faster innovations in biologic drugs.
Enhancing Biologics Through AI
The collaboration is expected to accelerate the development of Absci’s innovative de novo antibody design models. By utilizing AMD's advanced technology, Absci will enhance its proprietary IgDesign1 model, which represents a leap forward in the quest for effective biologic drugs.
Showcasing the Collaboration
The strategic partnership will be highlighted at the upcoming 43rd Annual J.P. Morgan Healthcare Conference, where McClain will discuss its implications on January 15. The conference will serve as a platform to demonstrate the capabilities of AMD's solutions in tackling complex biological applications.
About Absci Corporation
Absci focuses on merging AI solutions with laboratory techniques to enhance drug development processes. Its Integrated Drug Creation™ platform allows for the simultaneous optimization of multiple drug characteristics, significantly improving the probability of successful outcomes. Absci's ability to process billions of cells weekly ensures a rapid transition from AI-generated candidates to lab-validated results.
About AMD
AMD, a leader in high-performance computing and graphics, leverages its technology to support a myriad of industries, from healthcare to gaming. With over fifty years of innovation, AMD continuously strives to push the boundaries of technology, enabling profound advancements in various sectors.
Frequently Asked Questions
What is the significance of the partnership between Absci and AMD?
The partnership is crucial as it harnesses advanced AI technologies to improve the efficiency and effectiveness of drug discovery processes.
How much did AMD invest in Absci?
AMD invested $20 million in Absci through a private investment in public equity, underscoring the collaboration's importance.
What are some of the AI capabilities Absci aims to enhance?
Absci aims to enhance its AI-driven antibody design models, particularly the IgDesign1 model, using AMD's high-performance computing technologies.
When will the strategic partnership be presented to the public?
The strategic partnership will be showcased during the 43rd Annual J.P. Morgan Healthcare Conference.
What is Absci's Integrated Drug Creation™ platform?
This platform enables simultaneous optimization of various drug characteristics, increasing the likelihood of successful drug development.
